Vident Investment Advisory’s Adaptive Biotechnologies ADPT Stock Holding History

Vident Investment Advisory’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,467	Closed	-$124K	–	21
2023 Q2	$124K	Buy	18,467 +2,574	+16%	+$19.1K	﹤0.01%	1116
2023 Q1	$140K	Buy	15,893 +734	+5%	+$6.47K	﹤0.01%	1141
2022 Q4	$116K	Buy	15,159 +1,871	+14%	+$14.6K	﹤0.01%	1090
2022 Q3	$88K	Buy	13,288 +1,588	+14%	+$15K	﹤0.01%	1073
2022 Q2	$92K	Buy	+11,700	New	+$103K	﹤0.01%	1201
2021 Q3	–	Sell	-5,155	Closed	-$211K	–	1152
2021 Q2	$211K	Buy	+5,155	New	+$200K	0.01%	1035

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Vident Investment Advisory's ADPT Position: Q3 2023 in Review

Vident Investment Advisory sold out of Adaptive Biotechnologies (ADPT) in Q3 2023, closing a stake of 18,467 shares — an estimated $124K sold.

Vident Investment Advisory first reported a position in ADPT in Q2 2021 and held it in 6 quarters. The position peaked at $211K in Q2 2021. 190 funds tracked by Wall St. Rank hold ADPT as of Q3 2023.

Vident Investment Advisory reported no remaining Adaptive Biotechnologies position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 18,467 Adaptive Biotechnologies shares in Q3 2023, an estimated $124K.
Vident Investment Advisory first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 6 quarters.
Vident Investment Advisory's Adaptive Biotechnologies position peaked at $211K in Q2 2021.
190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.